CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
WLWT-Channel 5: Hamilton County and UC Law partner to lend...
July 1, 2022
Rob Wall, director of the Help Center for Hamilton County Municipal Court and a staff attorney for the UC College of Law, spoke with WLWT-TV for a story about the center's mission.
Lindner alum qualifies for World Track Championships
July 1, 2022
Annette Echikunwoke, MS ’19, recently finished third in the hammer throw at the 2022 USA Track & Field Outdoor Championships, qualifying her for this month’s World Championships in Eugene, Oregon.
How blood pressure affects stroke recovery
July 1, 2022
The University of Cincinnati's Eva Mistry, MD, is leading the BEST-II study researching how different blood pressure levels following a stroke affect recovery.